S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
OTCMKTS:BTCY

Biotricity Stock Forecast, Price & News

$3.99
-0.17 (-4.09%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.85
$4.15
50-Day Range
$2.70
$4.65
52-Week Range
$0.70
$4.99
Volume
205,378 shs
Average Volume
241,399 shs
Market Capitalization
$196.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.24
30 days | 90 days | 365 days | Advanced Chart
Receive BTCY News and Ratings via Email

Sign-up to receive the latest news and ratings for Biotricity and its competitors with MarketBeat's FREE daily newsletter.


Biotricity logo

About Biotricity

Biotricity, Inc. is a medical technology company, which is focused on biometric data monitoring solutions. It also involves in delivering, remote monitoring solutions to the medical, healthcare, and consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. The firm's FDA-approved Bioflux MCT technology, is comprised of a monitoring device and software components, which is made available to the market, in order to assess, establish and develop sales processes, and market dynamics. The company was founded by Waqaas Al-Siddiq and Peter McGoldrick on August 29, 2012 and is headquartered in Redwood City, CA.

Headlines

Biotricity (OTCMKTS:BTCY) Now Covered by HC Wainwright
November 23, 2021 |  americanbankingnews.com
Is Biotricity (NASDAQ:BTCY) Weighed On By Its Debt Load?
November 17, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Electric services
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:BTCY
Fax
N/A
Employees
24
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$196.03 million
Optionable
Not Optionable

Company Calendar

Today
12/04/2021
Next Earnings (Estimated)
2/09/2022
Fiscal Year End
3/31/2022

MarketRank

Overall MarketRank

1.87 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












Biotricity (OTCMKTS:BTCY) Frequently Asked Questions

Is Biotricity a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biotricity in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Biotricity stock.
View analyst ratings for Biotricity
or view top-rated stocks.

How has Biotricity's stock price been impacted by Coronavirus (COVID-19)?

Biotricity's stock was trading at $1.2250 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BTCY shares have increased by 225.7% and is now trading at $3.99.
View which stocks have been most impacted by COVID-19
.

When is Biotricity's next earnings date?

Biotricity is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for Biotricity
.

What price target have analysts set for BTCY?

4 brokerages have issued 1-year price objectives for Biotricity's shares. Their forecasts range from $6.00 to $7.00. On average, they expect Biotricity's share price to reach $6.75 in the next twelve months. This suggests a possible upside of 69.2% from the stock's current price.
View analysts' price targets for Biotricity
or view top-rated stocks among Wall Street analysts.

Who are Biotricity's key executives?

Biotricity's management team includes the following people:
  • Waqaas Al-Siddiq, Chairman, President & Chief Executive Officer
  • John Ayanoglou, Chief Financial Officer
  • Spencer LaDow, Vice President-Engineering
  • Amir Ali, Chief Development Officer

What other stocks do shareholders of Biotricity own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biotricity investors own include Axsome Therapeutics (AXSM), Bank of America (BAC), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Broadcom (AVGO), Cannabix Technologies (BLOZF), BioLineRx (BLRX), (CGC), CV Sciences (CVSI) and Charlotte's Web (CWBHF).

What is Biotricity's stock symbol?

Biotricity trades on the OTCMKTS under the ticker symbol "BTCY."

Who are Biotricity's major shareholders?

Biotricity's stock is owned by a variety of institutional and retail investors. Top institutional investors include HighTower Advisors LLC (0.13%), Moors & Cabot Inc. (0.08%), Geode Capital Management LLC (0.07%), Magnus Financial Group LLC (0.04%), Citadel Advisors LLC (0.03%) and Signature Wealth Management Partners LLC (0.03%).
View institutional ownership trends for Biotricity
.

Which major investors are buying Biotricity stock?

BTCY stock was bought by a variety of institutional investors in the last quarter, including HighTower Advisors LLC, Moors & Cabot Inc., Geode Capital Management LLC, Magnus Financial Group LLC, Citadel Advisors LLC, Signature Wealth Management Partners LLC, StoneX Group Inc., and National Asset Management Inc..
View insider buying and selling activity for Biotricity
or or view top insider-buying stocks.

How do I buy shares of Biotricity?

Shares of BTCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biotricity's stock price today?

One share of BTCY stock can currently be purchased for approximately $3.99.

How much money does Biotricity make?

Biotricity has a market capitalization of $196.03 million.

How many employees does Biotricity have?

Biotricity employs 24 workers across the globe.

What is Biotricity's official website?

The official website for Biotricity is www.biotricity.com.

How can I contact Biotricity?

The company can be reached via phone at (650) 832-1626.


This page was last updated on 12/4/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.